Levothyroxine sodium is a Small Molecule owned by Jerome Stevens Pharmaceuticals, and is involved in 6 clinical trials, of which 5 were completed, and 1 is ongoing.
Levothyroxine is a synthetic levoisomer of thyroxine (T4) that is similar to the endogenous hormone produced by the thyroid gland. In peripheral tissues, levothyroxine is deiodinated by 5'-deiodinase to form triiodothyronine (T3). T3 enters the cell and binds to nuclear thyroid hormone receptors; the activated hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration; thermogenesis; cellular growth and differentiation; and the metabolism of proteins, carbohydrates and lipids. T3 also exhibits cardiostimulatory effects.
The revenue for Levothyroxine sodium is expected to reach a total of $1.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Levothyroxine sodium NPV Report.
Levothyroxine sodium Overview
Levothyroxine sodium (Unithroid) is a synthetic thyroid hormone. It is formulated as the tablets for oral route of administration. Unithroid is indicated for the treatment of hypothyroidism.
Amneal Pharmaceuticals Overview
Amneal Pharmaceuticals (Amneal), formerly Amneal Pharmaceuticals, is a pharmaceutical company that develops, manufactures, markets and distribute pharmaceutical drug. It offering products includes generic and specialty pharmaceutical products. The company also offers product such as Activella, Albenza, Dexedrine, Nizatidine Oral Solution and Pyridiu in the area of oncology, inflammation and pain, central nervous system disorders, endocrinology and parasitic infections. Amneal offers products in various dosage forms such as oral solids and liquids, injectables, topicals, creams and ointments, transdermals, inhalation, ophthalmic and otic liquids and other device driven products. The company has operational presence in India, Switzerland, Ireland and the U.K. Amneal is headquartered in Bridgewater, New Jersey, the US.
The company reported revenues of (US Dollars) US$2,093.7 million for the fiscal year ended December 2021 (FY2021), an increase of 5.1% over FY2020. In FY2021, the company’s operating margin was 7.3%, compared to an operating margin of 4.6% in FY2020. In FY2021, the company recorded a net margin of 0.5%, compared to a net margin of 4.6% in FY2020. The company reported revenues of US$545.6 million for the third quarter ended September 2022, a decrease of 2.5% over the previous quarter.
Quick View – Levothyroxine sodium
|Highest Development Stage|